Stay updated with breaking news from Target Rwe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Target RWE, a leading real-world evidence (RWE) solutions company for the healthcare industry, shared results from a recent TARGET-NASH study...
/PRNewswire/ -- Real-world evidence leader Target RWE announced today COVID-19 data that has been recently published in the peer-reviewed medical journal...
Target RWE Research Presented at DDW 2021 Shows High Rates of Biologic Combination Therapy and Previous Biologic Exposure in IBD Population Poster of Distinction Award Granted to TARGET-IBD Research News provided by Share this article Share this article DURHAM, N.C., May 23, 2021 /PRNewswire/ -- Research presented today at Digestive Disease Week (DDW) 2021 evaluated the prevalence and predictors of immunomodulator use as concomitant therapy with two commonly prescribed biologics, vedolizumab (Entyvio) or ustekinumab (Stelara), in patients with inflammatory bowel disease (IBD). Data from Targe...
Patient Determinants for Histologic Diagnosis of Nonalcoholic Fatty Liver Disease in the Real World: A TARGET-NASH Study, aimed to determine patient characteristics that are predictive of having a diagnosis by biopsy versus a diagnosis using clinical criteria. Analyzing 3,474 participants with NAFLD from August 2016 to March 2019, the study found 67% had not had a liver biopsy. Analyzing 3,474 adult participants with nonalcoholic fatty liver disease (NAFLD) managed in usual clinical practice from August 2016 to March 2019, the study found 67% of the cohort had not had a liver biopsy. Predict...